Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015496 | 0.95 | GNRHR (0.90) | GNRHRMEN1KMT2A | |
| SCHEMBL7006963 | 0.94 | GNRHR (0.89) | GNRHRMEN1KMT2A | |
| SCHEMBL7497514 | 0.93 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7497509 | 0.92 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7015901 | 0.92 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7526343 | 0.92 | GNRHR (0.90) | GNRHRMEN1KMT2A | |
| SCHEMBL7011587 | 0.91 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7006144 | 0.91 | GNRHR (1.00) | GNRHRMEN1KMT2A | |
| SCHEMBL7497153 | 0.91 | GNRHR (0.85) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7497376 | 0.90 | GNRHR (0.99) | GNRHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6437132-B2 | INHIBITOR OF GONADOTROPIN RELEASING HORMONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-0781774-B1 | Prolactin production inhibitory agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6313301-B1 | CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
| US-6015789-A | LUTEINIZING HORMONE RELEASING HORMONE AGONIST AND A LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST IN COMBINATION, | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-6001850-A | HAVING GONADOTROPIN-RELEASING HORMONE ANTAGONISTIC ACTIVITY ARE USEFUL AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR THE PREVENTION OR TREATMENT OF SEVERAL HORMONE DEPENDENT DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5977132-A | GALACTORRHEA, HYPERPROLACTINEMIC OVULATION, PROLACTINOMA AND BRAIN TUMORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0906115-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997040846-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| EP-0781774-A2 | Prolactin production inhibitory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | GNRHR 1/4885MEN1 1739/4885KMT2A 1900/4885 |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | GNRHR 1/4885MEN1 1739/4885KMT2A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.